3 terminated, 1 completed. 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Terminated 3, Completed 1 |
Follow tilavonemab: new trials by email Literature Review of tilavonemab trials Research Report on tilavonemab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Extension Study of ABBV-8E12 in Early Alzheimer's Disease (AD) Tilavonemab - Alzheimer's Disease | Phase 2 | Terminated | AbbVie | 364 | 2019-03-22 | 2022-09-22 |
| An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP) ABBV-8E12, Placebo solution for IV infusion on Day 15 - Progressive Supranuclear Palsy (PSP) | Phase 2 | Terminated | AbbVie | 142 | 2018-01-24 | 2021-02-03 |
| A Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Participants With Early Alzheimer's Disease ABBV-8E12, placebo for ABBV-8E12 - Alzheimer's Disease | Phase 2 | Completed | AbbVie | 453 | 2017-01-26 | 2022-08-26 |
| A Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Subjects With Progressive Supranuclear Palsy (PSP) Placebo, ABBV-8E12 - Progressive Supranuclear Palsy | Phase 2 | Terminated | AbbVie | 378 | 2016-12-12 | 2021-02-03 |
Tauopathies (3) · Alzheimer Disease (2) · Supranuclear Palsy, Progressive (2) · Cognitive Dysfunction (1) · Dementia (1) · Memory Disorders (1) · Nervous System Diseases (1) · Neurodegenerative Diseases (1) · Pick Disease of the Brain (1)
AbbVie (4)
Australia (4) · Canada (4) · Italy (4) · United States (4) · Spain (3) · Belgium (2) · Denmark (2) · Finland (2) · Japan (2) · New Zealand (2) · Sweden (2) · France (1) · Germany (1) · Netherlands (1)
2016 (2), 2017 (1), 2018 (1)